Literature DB >> 19577636

Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults.

Rebecca C Brady1, John J Treanor, Robert L Atmar, Wendy A Keitel, Robert Edelman, Wilbur H Chen, Patricia Winokur, Robert Belshe, Irene L Graham, Diana Lee Noah, Kuo Guo, Heather Hill.   

Abstract

A total of 600 healthy adults > or =65 years were randomized to receive 2 vaccinations 1 month apart of a subvirion avian influenza A/H5N1 vaccine containing 3.75, 7.5, 15, or 45microg of hemagglutinin (HA) with or without aluminum hydroxide (AlOH). All formulations were safe. Groups given the vaccine with AlOH had more injection site discomfort. Dose-related increases in antibody responses were noted after the second vaccination. Antibody responses to the vaccine were not enhanced by AlOH at any HA dose level. A microneutralization titer > or =40 was observed in 36% and 40% of subjects who received 45microg of HA with or without AlOH, respectively.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19577636      PMCID： PMC2730950          DOI： 10.1016/j.vaccine.2009.06.057

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  12 in total

1.  Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use.

Authors:  N Hehme; H Engelmann; W Kuenzel; E Neumeier; R Saenger
Journal:  Virus Res       Date:  2004-07       Impact factor: 3.303

Review 2.  Antibody induction by influenza vaccines in the elderly: a review of the literature.

Authors:  W E Beyer; A M Palache; M Baljet; N Masurel
Journal:  Vaccine       Date:  1989-10       Impact factor: 3.641

3.  Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

Authors:  John J Treanor; James D Campbell; Kenneth M Zangwill; Thomas Rowe; Mark Wolff
Journal:  N Engl J Med       Date:  2006-03-30       Impact factor: 91.245

4.  Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.

Authors:  Robert L Atmar; Wendy A Keitel; Shital M Patel; Jacqueline M Katz; Dewei She; Hana El Sahly; Justine Pompey; Thomas R Cate; Robert B Couch
Journal:  Clin Infect Dis       Date:  2006-09-25       Impact factor: 9.079

5.  Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults.

Authors:  David I Bernstein; Kathryn M Edwards; Cornelia L Dekker; Robert Belshe; Helen K B Talbot; Irene L Graham; Diana L Noah; Fenhua He; Heather Hill
Journal:  J Infect Dis       Date:  2008-03-01       Impact factor: 5.226

6.  Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines.

Authors:  N Hehme; H Engelmann; W Künzel; E Neumeier; R Sänger
Journal:  Med Microbiol Immunol       Date:  2002-10-19       Impact factor: 3.402

7.  Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.

Authors:  Nega Ali Goji; Carrie Nolan; Heather Hill; Mark Wolff; Diana L Noah; Tracy B Williams; Thomas Rowe; John J Treanor
Journal:  J Infect Dis       Date:  2008-09-01       Impact factor: 5.226

8.  Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans.

Authors:  Kenneth M Zangwill; John J Treanor; James D Campbell; Diana L Noah; Jennifer Ryea
Journal:  J Infect Dis       Date:  2008-02-15       Impact factor: 5.226

Review 9.  MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile.

Authors:  Audino Podda; Giuseppe Del Giudice
Journal:  Expert Rev Vaccines       Date:  2003-04       Impact factor: 5.217

10.  Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells.

Authors:  Mark Throsby; Edward van den Brink; Mandy Jongeneelen; Leo L M Poon; Philippe Alard; Lisette Cornelissen; Arjen Bakker; Freek Cox; Els van Deventer; Yi Guan; Jindrich Cinatl; Jan ter Meulen; Ignace Lasters; Rita Carsetti; Malik Peiris; John de Kruif; Jaap Goudsmit
Journal:  PLoS One       Date:  2008-12-16       Impact factor: 3.240
View more
  30 in total

Review 1.  Inactivated influenza vaccines: recent progress and implications for the elderly.

Authors:  Valentina Parodi; Daniela de Florentiis; Mariano Martini; Filippo Ansaldi
Journal:  Drugs Aging       Date:  2011-02-01       Impact factor: 3.923

2.  Profiles of influenza A/H1N1 vaccine response using hemagglutination-inhibition titers.

Authors:  Robert M Jacobson; Diane E Grill; Ann L Oberg; Pritish K Tosh; Inna G Ovsyannikova; Gregory A Poland
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets.

Authors:  R Colby Layton; Nikolai Petrovsky; Andrew P Gigliotti; Zemmie Pollock; Jennifer Knight; Nathaniel Donart; John Pyles; Kevin S Harrod; Peng Gao; Frederick Koster
Journal:  Vaccine       Date:  2011-07-06       Impact factor: 3.641

4.  Differences in antibody responses between trivalent inactivated influenza vaccine and live attenuated influenza vaccine correlate with the kinetics and magnitude of interferon signaling in children.

Authors:  Raquel G Cao; Nicolas M Suarez; Gerlinde Obermoser; Santiago M C Lopez; Emilio Flano; Sara E Mertz; Randy A Albrecht; Adolfo García-Sastre; Asuncion Mejias; Hui Xu; Huanying Qin; Derek Blankenship; Karolina Palucka; Virginia Pascual; Octavio Ramilo
Journal:  J Infect Dis       Date:  2014-02-04       Impact factor: 5.226

Review 5.  Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts.

Authors:  Calvin C Willhite; Nataliya A Karyakina; Robert A Yokel; Nagarajkumar Yenugadhati; Thomas M Wisniewski; Ian M F Arnold; Franco Momoli; Daniel Krewski
Journal:  Crit Rev Toxicol       Date:  2014-10       Impact factor: 5.635

6.  Response of BALB/c mice to a monovalent influenza A (H1N1) 2009 split vaccine.

Authors:  Penghui Yang; Li Xing; Chong Tang; Weihong Jia; Zhongpeng Zhao; Kun Liu; Xiao Gao; Xiliang Wang
Journal:  Cell Mol Immunol       Date:  2010-02-01       Impact factor: 11.530

7.  Mono- and quadri-subtype virus-like particles (VLPs) containing H10 subtype elicit protective immunity to H10 influenza in a ferret challenge model.

Authors:  Peter Pushko; Xiangjie Sun; Irina Tretyakova; Rachmat Hidajat; Joanna A Pulit-Penaloza; Jessica A Belser; Taronna R Maines; Terrence M Tumpey
Journal:  Vaccine       Date:  2016-09-20       Impact factor: 3.641

8.  Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine.

Authors:  Innocent N Mbawuike; Robert L Atmar; Shital M Patel; David B Corry; Patricia L Winokur; Rebecca C Brady; Wilbur H Chen; Kathryn M Edwards; C Buddy Creech; Emmanuel B Walter; Sharon E Frey; Robert B Belshe; Johannes B Goll; Heather Hill; Wendy A Keitel
Journal:  Vaccine       Date:  2015-12-04       Impact factor: 3.641

Review 9.  Bench-to-bedside review: vaccine protection strategies during pandemic flu outbreaks.

Authors:  Joel V Chua; Wilbur H Chen
Journal:  Crit Care       Date:  2010-04-16       Impact factor: 9.097

10.  Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination.

Authors:  Daniel F Hoft; Kathleen Lottenbach; Johannes B Goll; Heather Hill; Patricia L Winokur; Shital M Patel; Rebecca C Brady; Wilbur H Chen; Kathryn Edwards; C Buddy Creech; Sharon E Frey; Tamara P Blevins; Rachelle Salomon; Robert B Belshe
Journal:  J Infect Dis       Date:  2016-07-20       Impact factor: 5.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.